Jazz Pharmaceuticals plc
JAZZ · XNASCIK 1232524fmd_1QE80HTQ87APFWNDPVMZ3DJYHCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 68 periods
Latest annual · FY2025
Millions- Total revenues
- 4,268
- Operating income
- (430)
- Net income
- (356)
- Free cash flow
- 1,297
Latest quarter · Q3 FY2026
Millions- Total revenues
- 1,243
- Operating income
- (413)
- Net income
- (483)
- Free cash flow
- 490
Daily close · JAZZIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions248.24 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +5.3%
- Revenue, 5 yearsFY2020 to FY2025
- +12.5%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Jazz Pharmaceuticals plc (JAZZ) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $4.3 billion | $4.1 billion | +4.9% | 10-K 2026-02-24 · proof |
| Operating income | -$430.2 million | $716.6 million | -160% | 10-K 2026-02-24 · proof |
| Net income | -$356.1 million | $560.1 million | -163.6% | 10-K 2026-02-24 · proof |
| Cash from operating activities | $1.4 billion | $1.4 billion | -2.9% | 10-K 2026-02-24 · proof |
| Free cash flow | $1.3 billion | $1.4 billion | -4.5% | 10-K 2026-02-24 · proof |
| Total assets | $11.7 billion | $12 billion | -2.9% | 10-K 2026-02-24 · proof |
| Total liabilities | $7.3 billion | $7.9 billion | -7.3% | 10-K 2026-02-24 · proof |
| Cash and cash equivalents | $1.4 billion | $2.4 billion | -42.3% | 10-K 2026-02-24 · proof |
| Total debt | $5.4 billion | $6.1 billion | -12.3% | 10-K 2026-02-24 · proof |
- What was Jazz Pharmaceuticals plc (JAZZ)'s revenue in fiscal 2025?
- Jazz Pharmaceuticals plc (JAZZ) reported revenue of $4.3 billion for fiscal 2025 (the year ended Dec 31, 2025), against $4.1 billion the year before (+4.9%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was Jazz Pharmaceuticals plc (JAZZ)'s operating income in fiscal 2025?
- Jazz Pharmaceuticals plc (JAZZ) reported operating income of -$430.2 million for fiscal 2025 (the year ended Dec 31, 2025), against $716.6 million the year before (-160%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was Jazz Pharmaceuticals plc (JAZZ)'s net income in fiscal 2025?
- Jazz Pharmaceuticals plc (JAZZ) reported net income of -$356.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $560.1 million the year before (-163.6%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was Jazz Pharmaceuticals plc (JAZZ)'s cash from operating activities in fiscal 2025?
- Jazz Pharmaceuticals plc (JAZZ) reported cash from operating activities of $1.4 billion for fiscal 2025 (the year ended Dec 31, 2025), against $1.4 billion the year before (-2.9%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was Jazz Pharmaceuticals plc (JAZZ)'s free cash flow in fiscal 2025?
- Jazz Pharmaceuticals plc (JAZZ) reported free cash flow of $1.3 billion for fiscal 2025 (the year ended Dec 31, 2025), against $1.4 billion the year before (-4.5%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are Jazz Pharmaceuticals plc (JAZZ)'s total assets?
- As of Dec 31, 2025, Jazz Pharmaceuticals plc (JAZZ) reported total assets of $11.7 billion, against $12 billion a year earlier (-2.9%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are Jazz Pharmaceuticals plc (JAZZ)'s total liabilities?
- As of Dec 31, 2025, Jazz Pharmaceuticals plc (JAZZ) reported total liabilities of $7.3 billion, against $7.9 billion a year earlier (-7.3%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are Jazz Pharmaceuticals plc (JAZZ)'s cash and cash equivalents?
- As of Dec 31, 2025, Jazz Pharmaceuticals plc (JAZZ) reported cash and cash equivalents of $1.4 billion, against $2.4 billion a year earlier (-42.3%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What is Jazz Pharmaceuticals plc (JAZZ)'s total debt?
- As of Dec 31, 2025, Jazz Pharmaceuticals plc (JAZZ) reported total debt of $5.4 billion, against $6.1 billion a year earlier (-12.3%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:JAZZ&period_type=annual&limit=5"Information only, not investment advice.